BioAtla (NASDAQ:BCAB) Posts Quarterly Earnings Results, Beats Estimates By $5.78 EPS

BioAtla (NASDAQ:BCAB) posted its quarterly earnings data on Friday. The company reported ($4.22) earnings per share for the quarter, topping the consensus estimate of ($10.00) by $5.78, FiscalAI reports.

BioAtla Price Performance

Shares of NASDAQ BCAB traded down $0.10 during trading hours on Friday, hitting $4.27. 27,443 shares of the company’s stock were exchanged, compared to its average volume of 45,986. BioAtla has a 1-year low of $3.92 and a 1-year high of $71.50. The stock has a market capitalization of $7.08 million, a price-to-earnings ratio of -0.08 and a beta of 0.81. The company’s 50-day moving average price is $6.25 and its 200-day moving average price is $19.75.

Hedge Funds Weigh In On BioAtla

Several large investors have recently added to or reduced their stakes in the company. Woodline Partners LP acquired a new position in BioAtla in the 1st quarter valued at approximately $26,000. Jane Street Group LLC raised its holdings in BioAtla by 55.4% in the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after acquiring an additional 123,597 shares in the last quarter. Vanguard Group Inc. raised its holdings in BioAtla by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after acquiring an additional 162,647 shares in the last quarter. Susquehanna International Group LLP raised its holdings in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in BioAtla in the 4th quarter valued at approximately $104,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised BioAtla to a “hold” rating in a research report on Saturday, April 11th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $200.00.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.